Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Clinical applications of FDG-probe guided surgery.

Vos CG, Hartemink KJ, Muller S, Oosterhuis JW, Meijer S, van den Tol MP, Comans EF.

Acta Chir Belg. 2012 Nov-Dec;112(6):414-8.

PMID:
23397821
2.

[Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].

Zhao TT, Li JG, Li YM.

Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):206-9. Chinese.

PMID:
17649638
3.

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.

Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, de Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ.

J Clin Oncol. 2009 Oct 1;27(28):4774-80. doi: 10.1200/JCO.2008.20.1822. Epub 2009 Aug 31.

PMID:
19720925
4.
5.

Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET).

Servois V, Mariani P, Malhaire C, Petras S, Piperno-Neumann S, Plancher C, Levy-Gabriel C, Lumbroso-le Rouic L, Desjardins L, Salmon RJ.

Eur J Surg Oncol. 2010 Feb;36(2):189-94. doi: 10.1016/j.ejso.2009.08.010. Epub 2009 Sep 22.

PMID:
19775851
6.

[Fluorodeoxyglucose F18(FDG)-probe guided biopsy].

Hartemink KJ, Muller S, Smulders YM, Petrousjka van den Tol M, Comans EF.

Ned Tijdschr Geneeskd. 2010;154:A1884. Dutch.

PMID:
20858312
7.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
8.

Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

BMC Cancer. 2008 Jun 9;8:165. doi: 10.1186/1471-2407-8-165.

9.

Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.

Capirci C, Rampin L, Erba PA, Galeotti F, Crepaldi G, Banti E, Gava M, Fanti S, Mariani G, Muzzio PC, Rubello D.

Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1583-93. Epub 2007 May 15.

PMID:
17503039
10.

Can the radiation dose to CT-enlarged but FDG-PET-negative inguinal lymph nodes in anal cancer be reduced?

Mai SK, Welzel G, Hermann B, Wenz F, Haberkorn U, Dinter DJ.

Strahlenther Onkol. 2009 Apr;185(4):254-9. doi: 10.1007/s00066-009-1944-5. Epub 2009 Apr 16.

PMID:
19370429
11.

Bone involvement in patients with lymphoma: the role of FDG-PET/CT.

Schaefer NG, Strobel K, Taverna C, Hany TF.

Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):60-7. Epub 2006 Sep 22.

PMID:
17021808
12.

Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.

Bastiaannet E, Uyl-de Groot CA, Brouwers AH, van der Jagt EJ, Hoekstra OS, Oyen W, Verzijlbergen F, van Ooijen B, Thompson JF, Hoekstra HJ.

Ann Surg. 2012 Apr;255(4):771-6. doi: 10.1097/SLA.0b013e31824a5742.

PMID:
22367443
13.

PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences.

Klaeser B, Mueller MD, Schmid RA, Guevara C, Krause T, Wiskirchen J.

Eur Radiol. 2009 Jul;19(7):1780-5. doi: 10.1007/s00330-009-1338-1. Epub 2009 Feb 24.

PMID:
19238391
14.

Intra-operative use of PET probe for localization of FDG avid lesions.

Molina MA, Goodwin WJ, Moffat FL, Serafini AN, Sfakianakis GN, Avisar E.

Cancer Imaging. 2009 Sep 29;9:59-62. doi: 10.1102/1470-7330.2009.0009.

15.

FDG-PET probe-guided surgery for recurrent retroperitoneal testicular tumor recurrences.

de Jong JS, van Ginkel RJ, Slart RH, Lemstra CL, Paans AM, Mulder NH, Hoekstra HJ.

Eur J Surg Oncol. 2010 Nov;36(11):1092-5. doi: 10.1016/j.ejso.2010.08.129. Epub 2010 Sep 15.

PMID:
20828977
16.

PET probe-guided surgery: applications and clinical protocol.

Gulec SA, Hoenie E, Hostetter R, Schwartzentruber D.

World J Surg Oncol. 2007 Jun 7;5:65.

18.

PET probe-guided surgery.

Gulec SA.

J Surg Oncol. 2007 Sep 15;96(4):353-7. Review.

PMID:
17726667
19.

PET-Probe: Evaluation of Technical Performance and Clinical Utility of a Handheld High-Energy Gamma Probe in Oncologic Surgery.

Gulec SA, Daghighian F, Essner R.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):9020-9027. Epub 2006 Jul 24.

PMID:
16865592
20.

A hand-held beta imaging probe for FDG.

Singh B, Stack BC Jr, Thacker S, Gaysinskiy V, Bartel T, Lowe V, Cool S, Entine G, Nagarkar V.

Ann Nucl Med. 2013 Apr;27(3):203-8. doi: 10.1007/s12149-012-0672-6. Epub 2012 Dec 11.

Supplemental Content

Support Center